J. Safra Sarasin Holding AG Decreases Position in Humana Inc. $HUM

Key Points

• J. Safra Sarasin Holding AG has significantly reduced its stake in Humana Inc. by 75.2%, leaving it with only 1,245 shares valued at $304,000.
• Institutional investors currently hold 92.38% of Humana's stock, with several firms increasing their positions in recent quarters.
• Analysts have mixed ratings on Humana, with a consensus target price of $291.21, while Guggenheim maintains a "buy" rating.

J. Safra Sarasin Holding AG lowered its holdings in Humana Inc. (NYSE:HUM - Free Report) by 75.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,245 shares of the insurance provider's stock after selling 3,768 shares during the period. J. Safra Sarasin Holding AG's holdings in Humana were worth $304,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of HUM. Revolve Wealth Partners LLC purchased a new position in Humana in the fourth quarter valued at about $202,000. Gateway Investment Advisers LLC lifted its holdings in shares of Humana by 53.4% in the 1st quarter. Gateway Investment Advisers LLC now owns 3,629 shares of the insurance provider's stock worth $960,000 after purchasing an additional 1,263 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in shares of Humana in the 1st quarter worth approximately $223,000. UMB Bank n.a. lifted its holdings in shares of Humana by 99.5% in the 1st quarter. UMB Bank n.a. now owns 373 shares of the insurance provider's stock worth $99,000 after purchasing an additional 186 shares during the last quarter. Finally, Washington Capital Management Inc. increased its position in Humana by 23.5% in the 1st quarter. Washington Capital Management Inc. now owns 2,100 shares of the insurance provider's stock valued at $556,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.

Wall Street Analysts Forecast Growth

HUM has been the topic of several analyst reports. Guggenheim restated a "buy" rating on shares of Humana in a research report on Friday. Weiss Ratings reiterated a "sell (d+)" rating on shares of Humana in a research report on Saturday, September 27th. Piper Sandler reduced their price objective on Humana from $288.00 to $272.00 and set a "neutral" rating for the company in a research note on Thursday, July 31st. Royal Bank Of Canada raised their price objective on Humana from $283.00 to $322.00 and gave the stock an "outperform" rating in a research note on Thursday, August 21st. Finally, Wall Street Zen lowered Humana from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Seven investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Humana currently has an average rating of "Hold" and a consensus target price of $291.21.

Humana Stock Performance

Shares of HUM stock opened at $284.00 on Friday. Humana Inc. has a 1-year low of $206.87 and a 1-year high of $315.35. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $34.16 billion, a price-to-earnings ratio of 21.80, a P/E/G ratio of 1.67 and a beta of 0.42. The stock's fifty day simple moving average is $274.76 and its 200-day simple moving average is $257.35.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion for the quarter, compared to analysts' expectations of $31.85 billion. During the same quarter in the prior year, the firm posted $6.96 EPS. The business's quarterly revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.2%. Humana's payout ratio is currently 27.17%.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.